Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
AIM ImmunoTech ( (AIM) ) has issued an announcement.
AIM ImmunoTech has filed an amended and restated Certificate of Incorporation, which supersedes all previous versions. This update may have implications for the company’s governance and operational structure.
The most recent analyst rating on (AIM) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Neutral.
AIM ImmunoTech’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, negative profitability, and weak balance sheet. Technical analysis and valuation also contribute to a low score, with negative momentum indicators and unattractive valuation metrics. The absence of earnings call data and corporate events leaves these areas unaddressed.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
Average Trading Volume: 111,127
Technical Sentiment Signal: Sell
Current Market Cap: $6.88M
For an in-depth examination of AIM stock, go to TipRanks’ Overview page.